Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.46 |
| ▸ | CCR5 | P51681 | 6/20 | 0.44 |
| ▸ | MGLL | Q99685 | 5/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22773313 | 0.85 | GPR119 (0.59) | — | |
| SCHEMBL22491546 | 0.85 | GPR119 (0.59) | — | |
| SCHEMBL5492177 | 0.82 | MGLL (0.47) | NPY2RDPP4DPP7MGLL | |
| SCHEMBL7859650 | 0.82 | MGLL (0.47) | NPY2RDPP4DPP7MGLL | |
| SCHEMBL23211867 | 0.81 | MGLL (0.40) | NPY2RDPP4DPP7MGLL | |
| SCHEMBL21381945 | 0.81 | MGLL (0.40) | NPY2RDPP4DPP7MGLL | |
| SCHEMBL22491347 | 0.78 | OPRD1 (0.54) | OPRD1 | |
| SCHEMBL23212042 | 0.77 | CYP3A4 (0.42) | DPP4DPP7 | |
| SCHEMBL21381659 | 0.77 | CYP3A4 (0.42) | DPP4DPP7 | |
| SCHEMBL25057228 | 0.77 | KMT2A (0.57) | NPY2RMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| EP-3717477-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-07-20 | — | — | EP | disclosed |
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | NPY2R 193/4885DPP4 3453/4885DPP7 4228/4885 |
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | LPXN, MLX, CCNY | NPY2R 398/4885DPP4 4493/4885DPP7 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.